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Alzheimer’s disease (AD) is the most common neurodegenerative disorder to date. Neuropathological hallmarks are β-amyloid
(Aβ) plaques and neuroﬁbrillary tangles, but the inﬂammatory process has a fundamental role in the pathogenesis of AD.
Inﬂammatory components related to AD neuroinﬂammation include brain cells such as microglia and astrocytes, the complement
system, as well as cytokines and chemokines. Cytokines play a key role in inﬂammatory and anti-inﬂammatory processes in AD.
An important factor in the onset of inﬂammatory process is the overexpression of interleukin (IL)-1, which produces many
reactions in a vicious circle that cause dysfunction and neuronal death. Other important cytokines in neuroinﬂammation are
IL-6 and tumor necrosis factor (TNF)-α. By contrast, other cytokines such as IL-1 receptor antagonist (IL-1ra), IL-4, IL-10, and
transforming growth factor (TGF)-β can suppress both proinﬂammatory cytokine production and their action, subsequently
protecting the brain. It has been observed in epidemiological studies that treatment with nonsteroidal anti-inﬂammatory drugs
(NSAIDs) decreases the risk for developing AD. Unfortunately, clinical trials of NSAIDs in AD patients have not been very fruitful.
Proinﬂammatory responses may be countered through polyphenols. Supplementation of these natural compounds may provide a
new therapeutic line of approach to this brain disorder.
1.Introduction
Originally described by Alois Alzheimer in 1907 [1], AD is
now the most common cause of dementia in the elderly. AD
aﬀects more than 4 million people in the United States [2].
It is estimated that 27 million people are aﬀected worldwide
[3]. As population life expectancy increases, the number of
aﬀected individuals is expected to triple by 2050 [2].
AD is a progressive brain disorder aﬀecting regions of
the brain that control memory and cognitive functions,
gradually destroying a person’s memory and ability to learn,
to reason, to communicate, and to carry out daily activi-
ties.
The two major neuropathologic hallmarks of AD are
extracellular Aβ plaques and intracellular neuroﬁbrillary
tangles. The production of Aβ, a seminal event in AD
[4], is a result of the cleavage of the amyloid precursor
protein (APP), volume of which is high in AD. APP has
important developmental functions in cell diﬀerentiation
and possibly in the establishment of synapses [5, 6], but
the function of APP in the adult brain is less clear. What
we do know, however, is that it is expressed by neurons
in response to cell injury. APP is, for example, a marker
for axonal damage after head injury [7, 8]. APP expression
is markedly increased in the aﬀected areas of the brain
in temporal lobe epilepsy [9]. Neuroﬁbrillary tangles are
composed of the tau (τ) protein. In healthy neurons, τ
is an integral component of microtubules, which are the
internal support structures that transport nutrients, vesicles,
mitochondria, and chromosomes from the cell body to the
ends of the axon and backwards. In AD, however, τ becomes
hyperphosphorylated. This phosphorylation allows τ to bind
together and form tangled threads [10].
Gliosis is also seen in AD; activated astrocytes and mi-
croglia are characteristically found in abundance near neu-
rons and plaques. Once activated, astrocytes and microglia2 The Scientiﬁc World Journal
produce several proinﬂammatory signal molecules, includ-
ing cytokines, growth factors, complement molecules, che-
mokines, and cell adhesion molecules [11–15]. This activa-
tion is thought to result from the glial reaction to the events
related to the ongoing deposition of Aβ [16–18].
2. InﬂammatoryProcess inAlzheimer’s Disease
Inﬂammation is a response to eliminate both the initial
cause of cell injury as well as the necrotic cells and
tissues resulting from the original insult. If tissue health
is not restored, inﬂammation becomes a chronic condition
that continuously erodes the surrounding tissues. In this
type of inﬂammation, tissue injury and healing proceed
simultaneously. The lateral damage normally caused tends to
accumulateslowly,sometimesevenasymptomaticallyduring
years. This can lead to severe tissue deterioration [19].
Brain inﬂammation is a pathological hallmark of AD.
However, the characteristic inﬂammatory features such as
swelling, heat, and pain are not present in the brain, and
therefore we refer here to chronic instead of acute inﬂam-
mation [14]. A characteristic feature of chronic inﬂamed
tissues is the presence of an increased number of monocytes,
as well as monocyte-derived tissue macrophages, that is,
microglia cells in the central nervous system (CNS) [14,
19].Inﬂammationclearlyoccursinpathologicallyvulnerable
regions of the AD brain, with increased expression of acute
phase proteins and proinﬂammatory cytokines which are
hardly evident in the normal brain [20–23]. Microglia,
astrocytes, and neurons are responsible for the inﬂammatory
reaction.
Activated cells strongly produce inﬂammatory mediators
such as proinﬂammatory cytokines, chemokines, macro-
phage inﬂammatory proteins, monocyte chemo-attractant
proteins, prostaglandins, leukotrienes, thromboxanes, coag-
ulation factors, reactive oxygen species (and other radi-
cals), nitric oxide, complement factors, proteases, protease
inhibitors, pentraxins, and C-reactive protein [13, 14, 18, 24,
25].
The hypothesis is that the intractable nature of the
Aβ plaques and tangles stimulates a chronic inﬂammatory
r e a c t i o nt oc l e a rt h i sd e b r i s[ 25]. These plaques contain dys-
trophic neurites, activated microglia, and reactive astrocytes
[14, 15, 26]. Aggregated amyloid ﬁbrils and inﬂammatory
mediators secreted by microglial and astrocytic cells con-
tribute to neuronal dystrophy [27, 28]. Chronically activated
glia can, furthermore, kill adjacent neurons by releasing
h i g h l yt o x i cp r o d u c t ss u c ha sr e a c t i v eo x y g e ni n t e r m e d i a t e s ,
nitric oxide (NO), proteolytic enzymes, complementary fac-
tors,orexcitatoryaminoacids[29].Inﬂammatorymediators
and a number of stress conditions, in turn, enhance APP
production and the amyloidogenic processing of APP to
induce amyloid-β-42 (Aβ-42) peptide production. These
circumstances also inhibit the formation of soluble APP
fraction that has a neuronal protective eﬀect [30–35]. On the
other hand, Aβ induces the expression of proinﬂammatory
cytokinesingliacellsinaviciouscycle[18,36],theactivation
of the complement cascade [37–39], and the induction
of inﬂammatory enzyme systems such as the inducible
nitric oxide synthase (iNOS) and the cyclooxygenase enzyme
(COX)-2. Several lines of evidence suggest that all of these
factors can contribute to neuronal dysfunction and cell
death, either alone or in concert [40–42].
2.1. Microglia. Microglia constitute around 10% of the
cells in the nervous system. They represent the ﬁrst line
of defense against invading pathogens or other types of
brain tissue injury. Under pathological situations, such as
neurodegenerative disease, stroke, traumatic injury, and
tumor invasion, these cells become activated, migrate, and
surround damaged or dead cells, and subsequently clear
cellular debris from the area. This action is similar to the
one performed by phagocytic active macrophages of the
peripheral immune system [43].
The current evidence points compellingly towards a
central role for inﬂammation in AD. This inﬂammation
is mediated by proinﬂammatory cytokines and would cre-
ate a chronic and self-sustaining inﬂammatory interaction
betweenactivatedmicrogliaandastrocytes,stressedneurons,
and Aβ plaques.
Microglia have been suggested to be preferentially asso-
ciated with certain amyloid plaque types [44]. Amyloid
peptides and their precursor protein APP are potent glial
activators [45, 46]. Disruption of the APP gene and its
proteolytic products delay and decrease microglial activation
[47]. This activation is directly dependent on the amyloid
load. Treatment with β-sheet breakers peptide results in
reduced brain inﬂammation [48].
Aβ is able to stimulate a nuclear factor-kappaB- (NFκB-)
dependent pathway that is required for cytokine production
[49]. The subsequent activation of extracellular signal-
regulatedkinase(ERK)andmitogen-activatedproteinkinase
(MAPK) pathways by Aβ binding to the microglial cell
surface induces proinﬂammatory gene expression and leads
to the production of cytokines and chemokines [50].
In some situations, the role of microglia has been found
to be beneﬁcial, since activated microglia can reduce Aβ
accumulation by increasing its phagocytosis, clearance, and
degradation [51, 52]. Microglia can also secrete a number of
soluble factors, such as the glia-derived neurotrophic factor
(GDNF), which are potentially beneﬁcial to the survival of
neurons [53]. It was proposed, therefore, that microglial
activation by active immunization might be a valid mecha-
nism for clearance of senile plaques [54]. However, because
ah u m a nt r i a lo fA β immunization led in some patients to
meningoencephalitis, this treatment has been discontinued
[55]. It was recently found that nasal vaccination in mice was
able to decrease Aβ. The extent of this reduction correlated
with microglial activation, suggesting that this may be a
promising approach for human Aβ immunization [56].
2.2. Astrocytes. Astrocytes are known to be important for Aβ
clearance and degradation, for providing trophic support to
neurons, and for forming a protective barrier between AβThe Scientiﬁc World Journal 3
deposits and neurons [57] .T h ep r e s e n c eo fl a r g en u m b e r s
of astrocytes associated with Aβ deposits in AD suggests that
these lesions generate chemotactic molecules that mediate
astrocyte recruitment.
Under certain conditions related to chronic stress, how-
ever, the role of astrocytes may not be beneﬁcial. A report
suggeststhatastrocytescouldalsobeasourceforAβ,because
they overexpress β-secretase of APP (BACE1) in response to
chronic stress [57]. In vitro and in vivo experiments suggest
though that inﬂammatory active astrocytes do not generate
signiﬁcant amounts of these molecules.
2.3.ComplementSystem. Thecomplementsystemrepresents
a complex and tightly regulated attack system designed
to destroy invaders and to assist in the phagocytosis of
waste materials. The components of this system carry out
four major functions: recognition, opsonization, inﬂamma-
tory stimulation, and direct killing through the membrane
attack complex [58]. Complement proteins interact with
cell surface receptors to promote a local inﬂammatory
response that contributes to the protection and healing of
the host. Complement activation causes inﬂammation and
cell damage, yet it is essential for eliminating cell debris and
potentially toxic protein aggregates [59].
The complement system consists of some 30 ﬂuid-
phase and cell-membrane-associated proteins that can be
activatedbydiﬀerentroutes.Theclassicalpathway(involving
C1q, C1r, C1s, C4, C2, and C3 components) is activated
primarily by the interaction of C1q with immune complexes
(antibody antigen), but activation can also be achieved after
interaction of C1q with nonimmune molecules such as
DNA, RNA, C-reactive protein, serum amyloid P, bacterial
lipopolysaccharides, and some fungal and virus membranes.
The initiation of the alternative pathway (involving C3,
factor B, factor D, and properdin) does not require the
presence of immune complexes and leads to the depo-
sition of C3 fragments on target cells. The molecular
network of classical and alternative complement cascades
with pattern recognition, proteolytic activation, functions
of fragments in phagocytosis, and stimulation of the host
immune defense has been reviewed in detail elsewhere [60–
62].
Many complement proteins and receptors can be syn-
thesized locally in the brain [63–66]. The complement
system activation has been observed in brain in diﬀerent
inﬂammatory and degenerative diseases, for example, AD,
multiple sclerosis, and stroke [59, 65, 67]. Surprisingly, the
most potent complement defense in human brain seems
to be located on the astrocytes which can express all the
components of classical and alternative pathways, such as
C1–C9,regulatoryfactorsB,D,H,I,andseveralcomplement
receptors, for example, C1qR, C3aR and C5aR [63, 65].
Microglial cells exhibit a more narrow set of complement
proteins, for example, C1q, C3 and receptors C1qR, CR3,
and C5aR, which support the phagocytic uptake of targeted
structures. Interestingly, neurons also express several regula-
tory proteins, such as factors H and S, as well as receptors
C1qR, C3aR and C5aR [65, 66, 68, 69].
Several research articles have reported that the com-
plement system of brain is activated in AD [59, 67, 70,
71]; furthermore, this system seems to be activated at a
very early stage of the disease. Aβ peptides can activate
the complement cascade without the presence of antibody.
They can additionally produce complement components
[72]. C1q protein is mainly localized in neurons, along
with neuritic plaques, both in the frontal cortex and in the
hippocampus [73]. Interestingly, C1q protein is present only
inthioﬂavin-positive amyloidplaquescontainingtheβ-sheet
conformation [73] showing that C1q may aﬀect the amyloid
aggregation process.
Moreover, there is an extensive literature demonstrating
that the complement system also has a neuroprotective
role in neuroinﬂammation [59, 60, 71, 74]. For example,
inhibition of the complement system could clearly increase
amyloidplaqueformationandtheneurodegenerationoccur-
ring in transgenic AD mice [75]. Complement C3 knockout
also aggravated the neuropathology in AD mice [76]. The
activity of C1q protein in the clearance of apoptotic cells and
Aβ aggregates into glial cells may well be the main cause for
neuroprotection.
2.4. Chemokines. Recent experiments have focused on un-
derstanding the role of chemokines and their receptors for
AD neuroinﬂammation.
The chemokine family consists of over 50 diﬀerent
molecules that confer chemotaxis, tissue extravasation, and
modulation of leukocyte function during inﬂammation [77,
78]. The importance of chemokine generation in AD brain
is underscored by the fact that these molecules may be
strong regulators of microglial migration and recruitment
of astrocytes to the area of neuroinﬂammation. They are
therefore responsible for the extent of local inﬂammation.
While it has been reported that chemokines exert phys-
iological action in the healthy brain [79], the majority of
studieshavefocusedontheexpressionpatternofchemokines
and their respective receptors in neurological diseases such
as multiple sclerosis, traumatic brain injury, and stroke. All
of these disorders share the disruption of the blood-brain
barrier as an important pathogenetic event subsequently
allowing peripheral leukocytes to inﬁltrate the lesion site
[80]. In contrast, no convincing evidence exists for blood-
brain barrier disruption or signiﬁcant leukocyte inﬁltration
in the AD brain.
However, several chemokines and chemokine receptors
have been found to be upregulated in the AD brain [81].
Chemokines may play an important role for recruiting
microglia and astroglia to the site of Aβ deposition. Aβ-
stimulated human monocytes generate chemokines such
as IL-8, monocyte chemoattractant protein- (MCP)-1,
macrophage inﬂammatory protein- (MIP)-1α and MIP-1β
in vitro, and microglia cultured from rapid autopsies of AD
and nondemented patients reveal an increased expression of
IL-8,MCP-1,andMIP-1αafterexperimentalexposuretoAβ.
Supporting the hypothesis that astrocytes actively contribute
to the inﬂammatory disease component, MIP-1α has been
detected in reactive astrocytes nearby Aβ plaques.4 The Scientiﬁc World Journal
2.5. Neurons. While neurons were traditionally believed to
be passive bystanders in neuroinﬂammation, more recent
evidence suggests that neurons can generate inﬂammatory
molecules.Thus,neuronscanserveassourceofcomplement,
COX-2-derived prostanoids [82–84], several cytokines [85–
93], and macrophage colony-stimulating factor (MCSF)
[94].
Although COX-2 expression is driven by physiological
synaptic activity [93] and therefore may be regarded as
physiologically expressed protein in a subclass of neurons,
inﬂammation induced by the generation of prostanoids may
well contribute to neuronal destruction. As a further factor,
expression of the inﬂammatory-induced enzyme iNOS has
been described in degenerating neurons in AD brains [95–
97]. Compelling evidence exists also for iNOS-related long-
termNOreleaseandNO-dependentperoxynitriteformation
[98]. Glial- and neuronal-derived NO and peroxynitrite have
been demonstrated to cause neuronal dysfunction and cell
death in vitro and in vivo [99, 100].
2.6. Cytokines. Cytokines are small and nonstructural pro-
teins with molecular weights ranging from 8,000 to
40,000Da. Originally called lymphokines and monokines
to indicate their cellular sources, it soon became clear that
the term “cytokine” was the best description, since nearly
all nucleated cells are capable of synthesizing these proteins
and, in turn, they are also capable of responding to these
molecules. There is no amino acid sequence motif or three-
dimensional structure that links cytokines. Their biological
activitiesallowusinturntogroupthemintodiﬀerentclasses.
Cytokines are secreted by a variety of immune cells
(e.g., T-lymphocytes, macrophages, natural killer cells) and
nonimmune cells (e.g., Schwann cells, ﬁbroblasts). The bio-
logical eﬀects induced by cytokines include the stimulation
or inhibition of cell proliferation, cytotoxicity/apoptosis,
antiviral activity, cell growth and diﬀerentiation, inﬂamma-
tory responses, and upregulation of expression of surface
membrane proteins. The main function of cytokines is the
regulationofT-celldiﬀerentiationfromundiﬀerentiatedcells
to T-helper 1 and 2, regulatory T cells, and T-helper 17
cells [101]. These regulatory proteins include ILs, interferons
(IFNs), colony stimulating factors (CSFs), TNFs, and certain
growth factors (GFs) [102, 103].
Many of these cytokines have already been shown to be
produced by neurons or glia and there are a number of
reports indicating changes in their levels in AD brain, blood,
and cerebrospinal ﬂuid (CF). Levels of IL-1α,I L - 1 β,I L - 6 ,
TNF-α, granulocyte-macrophage colony-stimulating factor
(GMSF), IFN-α, the type B of IL-8 receptor (IL-8RB), and
the receptor for CSF-1 are reportedly increased in AD brain
tissue [104, 105].
A number of interactions between cytokines and compo-
nents of the AD senile plaques have been reported suggesting
that a vicious circle might be generated [105]. Thus, the
Aβ protein of the plaques is said to potentiate the secretion
of IL-6 and IL-8 by IL-1β-activated astrocytoma cells, of
IL-6 and TNF-α by lipopolysaccharide- (LPS-) stimulated
astrocytes [106], and of IL-8 by monocytes. Cytokines can
also stimulate secretion of a number of the other proteins
found in senile plaques [105]. Moreover, synergistic eﬀects
mayalsooccurbetweencytokinesandAβ.Forexample,IFN-
γ is said to synergize with Aβ to cause the release of TNF-α
and reactive nitrogen species that are toxic to neurons, and
IL-1 is reported to increase the toxicity of Aβ in PC12 cells.
Some cytokines clearly promote inﬂammation and are
called proinﬂammatory cytokines, whereas other cytokines
suppress the activity of proinﬂammatory cytokines and
are called anti-inﬂammatory cytokines. For example, IL-4,
IL-10, and IL-13 are potent activators of B lymphocytes;
however, IL-4, IL-10, and IL-13 are also potent anti-
inﬂammatory agents. These are anti-inﬂammatory cytokines
by virtue of their ability to suppress genes for proinﬂamma-
tory cytokines such as IL-1, TNF, and the chemokines. IFN-
γ is another example of the pleiotropic nature of cytokines.
IFN-γ possesses antiviral activity, in the same way as IFN-
α and IFN-β.I F N - γ is also an activator of the pathway
aﬀecting cytotoxic T cells; however, IFN-γ is considered a
proinﬂammatory cytokine because it increases TNF activity
and induces NO. The concept that some cytokines function
would primarily be to induce inﬂammation while other
cytokines primary function would be to suppress inﬂamma-
tion is fundamental to cytokine biology and also to clinical
medicine.
The concept is based on the genes coding for the
synthesis of small mediator molecules that are upregulated
during inﬂammation. Therefore, a “balance” between the
eﬀects of proinﬂammatory and anti-inﬂammatory cytokines
is thought to determine the outcome of disease, whether in
the short term or long term. In fact, data from some studies
suggestthatsusceptibilitytodiseaseisgeneticallydetermined
by the balance or expression of either proinﬂammatory or
anti-inﬂammatorycytokines.Itshouldbeconsideredthough
that some gene linkage studies are often diﬃcult to interpret.
2.6.1. Major Proinﬂammatory Cytokines. The cytokine class
of inﬂammatory mediators is secreted by microglia and
astrocytes surrounding Aβ neuritic plaques. Their produc-
tion is increased in inﬂammatory states and they function
by regulating the intensity and duration of the immune
response [13]. The IL-1 family of cytokines includes two
agonist proteins, IL-1α and IL-1β,w h i c ht r i g g e rc e l la c t i v a -
tion upon binding with speciﬁc membrane receptors. Also
included is IL-1ra, which is a glycosylated secretory protein
of 23kDa that counteracts the action of IL-1 [107].
IL-1 is an important initiator of the immune response,
playing a key role in the onset and development of a complex
hormonal and cellular inﬂammatory cascade. Elevated IL-
1β has been detected in the CF and brain parenchyma
within the early hours after brain injury in both humans and
rodents [108, 109]. Nonetheless, IL-1 has been documented
to play a role in neuronal degeneration. In astrocytes, IL-1
induces IL-6 production, stimulates iNOS activity [110], and
induces the production of MCSF. In addition, IL-1 enhances
neuronal acetylcholinesterase activity, microglial activation
and additional IL-1 production, astrocyte activation, and
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astrocytes, thereby establishing a self-propagating cycle [18,
111].
IL-6isamultifunctionalcytokinethatplaysanimportant
role in host defense [112], with major regulatory eﬀects
upon the inﬂammatory response [113]. IL-6 belongs to the
neuropoietin familyofcytokines[114],andithasbothdirect
and indirect neurotrophic eﬀects on neurons [115]. IL-6
promotes astrogliosis [116], activates microglia [117], and
stimulates the production of acute phase proteins [118].
TNF-α plays a central role in initiating and regulating
the cytokine cascade during an inﬂammatory response. It
is produced as a membrane-bound precursor molecule of
26kDa that is cleaved by the TNF-α converting enzyme to
produce a 17kDa active cytokine [119] .T h el e v e l so fT N F -
α expression in the healthy brain are low, making it diﬃcult
to determine its precise role under physiological conditions.
In inﬂammatory or disease states, TNF-α along with several
otherproinﬂammatorymediatorsandneurotoxicsubstances
are predominantly produced by activated microglia. Neu-
ronal production of TNF-α has been demonstrated [86],
although brain-derived TNF-α is mostly synthesized by glial
cells in response to pathological stimuli. Glial cells secrete
both TNF-α and IL-1, which in turn, activate these cells in an
autocrinemannertoinducefurthercytokineproductionand
astrogliosis. TNF-α, on the other hand, has been reported to
have neuroprotective properties [14] in the AD brain.
In addition to the general role of cytokines, AD-speciﬁc
interactions of certain cytokines and chemokines with Aβ
may be pathophysiologically relevant. For example, IL-1 can
regulate APP processing and Aβ production in vitro [120].
In turn, ﬁbrillar Aβ h a sb e e nr e p o r t e dt oi n c r e a s en e u r o t o x i c
secretory products, proinﬂammatory cytokines, and reactive
oxygen species [121–123]. Cultured rat cortical glia exhibit
elevated IL-6 mRNA after exposure to the carboxy-terminal
105aminoacidsofAPP[124].Inthesamesituation,IL-1,IL-
6, TNF-α,M I P - 1 α and MCP-1 increase in a dose-dependent
manner after cultured microglia are incubated with Aβ.T h e
production of interleukins, other cytokines, and chemokines
may also lead to microglial activation, astrogliosis, and fur-
ther secretion of proinﬂammatory molecules and amyloid,
thus perpetuating the cascade [50].
2.6.2. Major Anti-Inﬂammatory Cytokines. As e c o n dg e n -
eral category of cytokine action is manifested by anti-
inﬂammatorycytokinessuchasIL-1ra,IL-4,IL-10,andTGF-
β. These inhibitory cytokines can suppress proinﬂammatory
cytokine production and action, an eﬀect that is critical to
the concept of balance among pro- and anti-inﬂammatory
cytokines.TheclinicalconsequenceofaCNSdisregulationin
this balance (high levels of proinﬂammatory cytokines, low
levels or activity of anti-inﬂammatory cytokines) can lead
to cytokine production and synergistic cytokine actions and
can induce an ampliﬁcation cycle of cellular activation and
cytotoxicity[125].Thus,bothcytokine-cytokineinteractions
and cytokine interactions with existing AD pathology may
play critical roles in AD neuroinﬂammation.
IL-1ra is a 152-amino-acid protein that functions as a
speciﬁc inhibitor of the two other functional members of the
IL-1 family, IL-1α and IL-1β [126, 127]. IL-1ra is produced
by monocytes and macrophages and is released into the
systemic circulation, blocking the action of IL-1α and IL-
1β functional ligands by competitive inhibition at the IL-
1 receptor level. IL-1ra binds with equal or greater aﬃnity
thandoesIL-1αandIL-1β tothetype1(80kDa)membrane-
bound IL-1 receptor. In contrast, IL-1ra does not bind with
high aﬃnity to the type II (68kDa) IL-1 receptor [128, 129].
The biological actions of IL-1β are regulated in vivo by
IL-1ra [130]. This action is performed by preventing the
binding of IL-1β to IL-1 type I receptor (IL-1RI) [131]. In
vitro, IL-1ra suppresses IL-1β-induced TNF-α production
and iNOS expression in astrocytes [132]. IL-1ra also protects
against IL-1β neurotoxicity [133]. Furthermore, in vivo IL-
1ra attenuates ischaemic and excitotoxic neuronal damage
[134].
IL-4 is a 20-kDa glycoprotein produced by mature Th2
cells and cells from the mast cell or basophil lineage, which
is able to inﬂuence Th-cell diﬀerentiation. IL-4 drives Th2
responses, mediates the recruitment and activation of mast
cells, and stimulates the production of IgE antibodies via the
diﬀerentiation of B cells into IgE-secreting cells [135, 136].
Also, IL-4 has marked inhibitory eﬀects on the expression
and release of the proinﬂammatory cytokines, it is able to
blockorsuppressthemonocyte-derived cytokines,including
IL-1, TNF-α, IL-6, IL-8, and MIP-1α [135, 136], and it
stimulatesthesynthesisofIL-1ra[137].Othermechanismby
which IL-4 exerts its neuroprotective eﬀect might be related
totheinhibition ofIFN-γ andtheconsequentdecreaseinthe
concentration of TNF-α and NO [138].
IL-10 is one of the main anti-inﬂammatory cytokines.
IL-10 mRNA is detectable in the frontal and parietal lobe
of the normal brain [139] and has been suggested to play
an important role in neuronal homeostasis and cell survival
[140]. IL-10 mediates on cells by interacting with speciﬁc cell
surface receptors (IL-10Rs), present on all the major glial cell
populations in the brain [140], and it limits inﬂammation by
reducing the synthesis of proinﬂammatory cytokines such as
IL-1andTNF-α,bysuppressingcytokinereceptorexpression
and by inhibiting receptor activation in the brain. Aβ does
not seem to stimulate IL-10 production by glial cells in vitro
[141], but preexposure of glial cells to IL-10 inhibits Aβ-
or LPS-induced production of proinﬂammatory cytokines
[139], suggesting that IL-10 receptors are present in cul-
tured glial cells [142]. IL-10 inhibits monocyte/macrophage-
derived TNF-α, IL-1, IL-6, IL-8, IL-12, GMSF, MIP-1α,a n d
MIP-2α [143–145]. In addition to these activities, IL-10
attenuatessurfaceexpressionofTNFreceptorsandpromotes
the shedding of TNF receptors into the systemic circulation
[146, 147].
TGF-β is synthesized as an inactive precursor and
requires activation before exerting its eﬀect [148]. The
active molecule is a 25-kDa homodimer of two 12.5-kDa
disulﬁde-linked monomers and it belongs to a superfamily
of >20 distinct dimeric proteins that share a similar structure
[149]. TGF-β is an important regulator of cell proliferation,
diﬀerentiation, and formulation of the extracellular matrix
[150]. TGF-β is capable of converting an active site of
inﬂammation into one dominated by reparations [150]. In6 The Scientiﬁc World Journal
addition, TGF-β suppresses the proliferation and diﬀerenti-
ation of T cells and B cells and limits IL-2, IFN-γ,a n dT N F
production.
All three known mammalian isoforms of TGF-β, that
is, TGF-β1, 2, and 3, are expressed in the CNS and have
been implicated in the pathogenesis of AD. TGF-β has
been shown to modulate a wide range of processes that
are implicated in AD, including brain injury response and
astrocytosis, brain inﬂammatory response and microglial
activation, extracellular matrix production, accumulation
and regional distribution of amyloid, regulation of known or
potential AD risk factors (e.g., APP, COX-2), and inhibition
of cell death. For example, AD TGF-β1h a sb e e nd e t e c t e d
in plaques [151], and higher TGF-β1 levels were found in
cerebrospinal ﬂuid [152]a n ds e r u m[ 153]o fA Dc a s e st h a n
in nondemented controls. Immunostaining for TGF-β2w a s
observed in reactive astrocytes, ramiﬁed microglia, and a
portion of tangle-bearing neurons in AD cases [154]. Finally,
it should be noted that immunoreactivities for TGF-β1a n d2
receptors were higher in reactive glia in AD cases than in the
nondemented controls [155].
2.7. Growth Factors. Growth factors are proteins, which sup-
portthesurvivalofcellsofthecentralandperipheralnervous
system. Growth factors play a role in the development of the
brain, they stimulate axonal growth and regulate the growth
of diﬀerent kinds of cells in the brain and periphery. In many
cases, the same growth factor and corresponding receptor
signalling system may thus serve a number of diﬀerent
functions in the body.
Nerve growth factor (NGF) is the most potent growth
factor able to counteract cell death of cholinergic neurons
in vitro and in vivo [156]. Increased NGF has been found
in the CF of AD patients [157–159]. In spite of the fact
that NGF disfunction has been suggested in the develop-
ment of AD, NGF knockout mice have not shown clear
cognitive deﬁcits. NGF has been considered, nevertheless,
as a candidate for treating AD puriﬁed NGF, in fact, it was
infused in some AD patients [160]. NGF is upregulated
in brains [161] and CSF [158] of AD patients, while the
high-aﬃnity NGF receptor trkA is downregulated [162].
Interestingly, the increase of NGF was speciﬁc for AD
compared to healthy controls and was dependent on the
extent of neurodegeneration as expressed by the phospho-
tau181/Aβ-42 ratio [157]. Although NGF data alone did
not reveal a signiﬁcant diﬀerence, the comparison of NGF
in AD patients having a phospho-tau181/Aβ-42 ratio >10
with healthy control subjects (ratio <6) revealed a signiﬁcant
diﬀerence [157]. This might suggest that NGF accumulates
in neurodegeneration only at a certain stage of the disease.
Furthermore, vascular endothelial growth factor (VEGF)
is an important growth factor, which regulates angiogenesis
in the nervous system, and it is increased [163, 164]
in AD, resulting in enhanced microvascular density when
developing the disease. The disregulation of other growth
factors may also contribute to AD. For example, platelet-
derived growth factor (PDGF), which is mitogenic for cells
of mesenchymal origin, has been found to upregulate APP in
the hippocampus by inducing secretases [165–167]. Insulin-
like growth factor-I (IGF-I) regulates Aβ levels and displays
protective eﬀects against Aβ toxicity [168, 169]. Finally,
members of the TGF-β family interact with Aβ, contributing
toitstoxicityorconstitutingariskforcerebralAβangiopathy
[170, 171].
3. Anti-Inﬂammatory Therapy and
Alzheimer’sDisease
Based on the compelling evidence that inﬂammatory pro-
cesses are involved in the pathogenesis of AD, research
has looked into the use of anti-inﬂammatory drugs as a
treatment option for patients with AD. Drugs such as the
NSAIDs and glucocorticoid steroids have been studied to
determine if they oﬀer any beneﬁts to AD patients.
3.1. NSAIDs. The NSAIDs are a family of drugs that
include the salicylate, propionic acid, acetic acid, fena-
mate, oxicam, and the COX-2 inhibitor classes. They have
analgesic, antipyretic, and anti-inﬂammatory properties by
inhibiting the COX enzyme that catalyses the initial step
in the conversion of arachidonic acid to several eicosanoids
including thromboxanes, leukotrienes, and prostaglandins.
Eicosanoids play major regulatory roles in cell functions
including immune and inﬂammatory functions.
The COX enzyme is known to exist as two isoenzymes,
COX-1 and COX-2, both of which occur in the brain
but whose functions are not well understood. COX-1 is
responsible for homeostatic production of prostanoids.
COX-2 is inducible and its expression can be modiﬁed
depending on the stimuli but may also have a role in the
development of homeostasis [172]. With the exception of
COX-2 inhibitors, all classes of NSAIDs inhibit both COX-
1 and COX-2 enzymes. COX-2 inhibitors, as their name
implies, selectively inhibit the COX-2 enzyme.
Epidemiological evidence indicates that NSAIDs may
lower the risk of developing AD [173–176]. Since patients
with rheumatoid arthritis and osteoarthritis are typically
treated and are exposed to NSAIDs for a long period of
time, epidemiological studies have looked into the asso-
ciation of these diseases and AD. Many of those studies
showed an inverse relationship between having arthritis (and
being treated with NSAIDs) and AD [177]. A prospective
population-based study has also shown a signiﬁcant reduc-
tionintheriskofADinsubjectswhohadtakenNSAIDsfora
cumulative period of 24 months or more [178]. Postmortem
studies have also shown the ability of NSAIDs to reduce the
inﬂammation that is consistently seen in AD brain tissue
[179]. A possible mode of action for the eﬀectiveness of
NSAIDs is by the blockage of COX-2 in the brain. It has
been shown that COX-2 mRNA is considerably upregulated
in aﬀected areas of AD brain [180, 181], with COX-2
immunoreactivity located mainly in pyramidal neurons in
the cerebral cortex and the hippocampal formation [182],
suggesting the involvement of COX-2 in AD.
T h eN S A I D sh a v eb e e ns h o w nt od i r e c t l ya ﬀect the
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ibuprofen, indomethacin, and sulindac sulphide were shown
to decrease the Aβ-42 peptide by up to 80% in cultured cells
(eﬀect not observed with naproxen, celecoxib, or aspirin)
[183]. Since not all NSAIDs had this eﬀect, it would seem
that this eﬀect occurs through a process that is independent
of their anti-inﬂammatory COX activity. Treatment of mice
overexpressingAPPwithibuprofenresultedinareductionof
the amyloid plaque load in the cortex along with a reduction
of microglial activation in the mice [184]. A study analyzing
the ability of common NSAIDs and the enantiomers of
ﬂurbiprofen to lower Aβ levels in neuroglioma cells and in
AAP transgenic mice showed that some but not all of the
NSAIDstestedloweredtheAβincellsandwereabletoreduce
the Aβ levels in the mice [185]. Neurons that were pretreated
with ibuprofen showed decreased production of Aβ upon
exposure to the cytokine TNF-α as compared to untreated
neurons [186]. Another study showed that neurons that
were treated with COX-1 inhibitors, such as ibuprofen and
acetyl salicylic acid, were more resistant to the eﬀects of Aβ
than neurons that were treated by COX-2 inhibitors [187].
This study also showed a decrease in the production of
prostaglandinE2intheneuronsbytreatmentofbothCOX-1
and COX-2 inhibitors.
NSAIDs may also function by activating the peroxiso-
mal proliferators-activated receptors (PPARs), a group of
nuclear hormone receptors that act to negatively inhibit
the transcription of proinﬂammatory genes. For example,
PPARα agonists have been shown to inhibit IL-6, TNF-α,
andCOX-2expressionincellcultures[188].PPARγ hasbeen
shown to inhibit microglial activation and a multitude of
proinﬂammatory agents such as cytokines, NOS, and COX-2
[189].
Unfortunately, clinical trials of NSAIDs in AD patients
have not been very fruitful [190]. This was especially dis-
appointing in the case of COX-2 inhibitors. A randomized,
double-blind, placebo-controlled trial assessing the eﬀect of
the COX-2 inhibitor rofecoxib and the COX-1 and COX-
2 inhibitor naproxen versus placebo on AD progression
did not slow the cognitive decline of patients with mild-
to-moderate AD [191]. Another randomized, double-blind,
placebo-controlled trial using the COX-2 inhibitor rofecoxib
did not slow the decline of AD [192]. Speciﬁc Aβ-lowering
NSAIDs may need to be used in future clinical trials to see
if they are clinically as eﬀective. One possible hypothesis
wouldbeforNSAIDstohelpinreducingtheincidenceofthe
disease, but NSAIDs would not be as useful once the disease
occurs.
3.2. Glucocorticoid Steroids. Steroids are considered to be
potent anti-inﬂammatory agents and function by regulat-
ing the transcription of assorted inﬂammatory molecules,
inhibiting the production of enzymes which mediate
prostaglandin production. Steroids also have an eﬀect by
reducing the expression of cytokines and complement pro-
teins that are proinﬂammatory [179]. It is therefore surpris-
ing to ﬁnd that the epidemiological data for the eﬀect of the
use of glucocorticoid steroids in the AD brain show either a
very weak beneﬁt in the patient [193] or might even show
a possible harmful eﬀect [194]. While glucocorticoids were
shown to inhibit Aβ induction of chemokines and cytokines
in the CNS [195], a randomized, placebo-controlled trial
was conducted to determine whether prednisone treatment
slowedtherateofcognitivedeclineinADpatients.Thisstudy
showed that there was no diﬀerence in cognitive decline
between the treated and the control groups [196]. Indeed,
total levels of the glucocorticoid cortisol in the CF and
serum of AD patients were found to be signiﬁcantly elevated
whencomparedtonondementedcontrolpatients[197,198],
suggesting that increased levels of steroids may be associated
with AD.
4. Flavonoids: A Natural Strategy
A mean by which the proinﬂammatory responses may
be counteracted, and therefore AD’s severity reduced, is
throughagroupofnaturalplant-derivedcompoundsknown
as polyphenols; speciﬁcally those known as “ﬂavonoids”
derivedfromthegreenteaplant.Flavonoidsarealargefamily
of compounds synthesized by plants that have a common
chemical structure [199].
Greenteaﬂavonoidslikeepigallocatechingallate(EGCG)
appear to promote downregulation of innate immune cell
functions. Putative mechanisms of ﬂavonoid action on the
innate immune system include direct free radical scavenging
[200, 201] as well as a reduction of inﬂammatory cytokine
production of molecules including TNF-α,I L - 1 β,a n d
prostaglandinE2[202].Onlinewiththeseﬁndings,activated
microglia cocultured with neuroblastoma cells were less
neurotoxic inthepresenceoftheﬂavonoidﬁsetin,suggesting
that some ﬂavonoids may act to inhibit proinﬂammatory
innate immune responses [202, 203].
Some ﬂavonoids, including EGCG, may modulate T-
cell response by downregulating innate immune response,
by stimulating the cytokines that promote Th1 immunity
(e.g., TNF-α) and by promoting Th2 cytokines. These eﬀects
are thought to be mediated in part through the downreg-
ulation of NFkB signaling [204–206]. EGCG inhibits TNF-
α-induced production of MCP-1 from vascular endothelial
cells [207]. Furthermore, EGCG also displays the ability
to suppress neuron death mediated by activated microglia
[208].
Although ﬂavonoid-rich diets and ﬂavonoid administra-
tion prevent cognitive impairment associated with inﬂam-
mation in animal studies [209–211], retrospective cohort
studies are inconsistent in showing an inverse association
between dietary ﬂavonoid (e.g., green tea) intake and
dementia or neurodegenerative disease risk in humans [212–
215]. An epidemiological study of Dutch adults, for example,
found that total dietary ﬂavonoid intake was not associated
with the risk of developing AD [212, 213]. This relation does
not include current smokers whose risk of AD decreased
by half for every 12mg increase in daily ﬂavonoid intake.
Elderly French men and women with the lowest ﬂavonoid
intakes, on the other hand, had a 50% higher risk of
developing dementia over the next 5 years than those
with the highest intakes [214]. Thus, future human studies8 The Scientiﬁc World Journal
(ideally randomized clinical trials) will be required. These
studies should involve supplementation with relatively high
doses of speciﬁc puriﬁed ﬂavanoids to shed light to the
apparent inverse risk relationship with AD (and whether this
occurs by reducing inﬂammation) and also to determine if
such compounds are therapeutically beneﬁcial.
5. Conclusions
Increasing concurrent evidence suggests that inﬂammation
signiﬁcantly contributes to the pathogenesis of AD. The
generation and secretion of proinﬂammatory mediators
may interact at multiple levels with neurodegeneration.
Thus, proinﬂammatory cytokines may not only contribute
to neuronal death, but they might also inﬂuence classical
neurodegenerative pathways such as APP processing and τ
phosphorylation.
The concomitant release of anti-inﬂammatory mediators
may partly antagonize this action ultimately leading to
chronic disease. Future studies need to determine whether
the course of AD can be inﬂuenced by anti-inﬂammatory
treatment strategies, and clinically novel approaches to
analyze early neuroinﬂammation in the human brain are
needed to improve how to monitor and control treatment
strategies that are targeting inﬂammatory mechanisms.
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